Tim Fugmann | CSO and Co-founder
Alithea Bio
Tim Fugmann, CSO and Co-Founder of Alithea Biotechnology, holds a PhD from ETH Zurich and was 10 years in biotech industry in Switzerland before being appointed Prof. for mass spectrometry-based proteomics in Giessen, Germany. For many years, he is studying HLA-presented peptides in health and disease to discovery novel targets for immunotherapy, provide evidence for safety of HLA-peptide targeted therapeutics and building solutions for clinical applications of the technology. In his CSO role, he is driving partnerships with drug developers and guiding innovative technology developments to bring immunopeptidomics into clinical routine.
Appearances:
Festival of Biologics Day 1 @ 14:40
Clinical application of HLA peptidomics for precision immunotherapy
Prof. Dr. Tim Fugmann has studied technical Biology at the University of Stuttgart and later did his PhD at the ETH Zürich on "Innovative methodologies for the proteomic discovery of vascular markers in cancer and kidney disease". After the PhD he joined Philochem AG as head of target discovery with the aim to discover novel targets for pharmaceutical intervention. To better understand why certain patients respond to immunotherapy (which are developed by Philogen, the mother company of Philochem), his group implemented state-of-the-art HLA peptidomics technology for the study of T cell-cancer cell interactions. After nine years in industry, he moved to Berlin and joined the Max-Delbrück-Centrum for molecular medicine to work on bringing TCR T cell therapeutics from academic research into clinical trials. In February 2021 he was appointed to Professor for Proteomic with Focus on Mass Spectrometry at the JLU Giessen. The group worked with the state-of-the-art Orbitrap Fusion Eclipse mass spectrometer.
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events